20 Zoetis Insiders Awarded 72,725 Shares in Coordinated Stock Grants

Twenty insiders at animal health giant Zoetis Inc. (NYSE: ZTS) received stock awards totaling 72,725 shares on February 18, 2026, according to recent SEC filings. The coordinated grants appear to be part of the company's annual equity compensation cycle, with CEO Kristin Peck receiving the largest allocation at 28,072 shares.

The Trades

All 20 transactions occurred on the same date—February 18, 2026—and were structured as stock awards rather than open market purchases or sales. The awards ranged from 1,936 shares for board members to 28,072 shares for CEO Kristin Peck. At current market prices around $165 per share, the total value of the awarded shares would exceed $11.9 million, though the filings list the transaction prices at $0.00, typical for restricted stock unit (RSU) grants.

The uniform timing and structure of these transactions indicate they're part of Zoetis's regular equity compensation program rather than discretionary insider buying or selling. Most board members received identical grants of 1,936 shares, while executive vice presidents received varying amounts based on their roles and compensation packages.

Who's Trading

The insider group represents a comprehensive cross-section of Zoetis leadership, including both executive officers and independent board members. CEO Kristin Peck led the group with 28,072 shares awarded, representing nearly 40% of the total shares distributed. Executive Vice Presidents received awards ranging from 2,197 shares to 4,148 shares, with variations likely reflecting different tenure, performance metrics, or compensation levels.

Notable executives receiving grants include:

• Julie Fuller, Executive Vice President (3,626 shares)
• Kevin Esch, Executive Vice President (4,026 shares)
• Nicholas Ashton, Executive Vice President (4,148 shares)
• Roxanne Lagano, Executive Vice President (3,664 shares)
• Keith Sarbaugh, Executive Vice President (2,674 shares)

The board member recipients, including Sanjay Khosla, Paul Bisaro, and Michael McCallister, each received the standard 1,936-share grant. This consistency in board compensation reflects typical corporate governance practices for non-employee director equity awards.

What to Watch

While these awards don't represent immediate buying or selling pressure—RSUs typically vest over multiple years—they do signal the company's confidence in using equity as a significant compensation component. The broad participation across 20 insiders suggests alignment between management, the board, and shareholder interests.

For context, Zoetis has performed well in recent years, benefiting from strong pet ownership trends and livestock health demand. The company's stock has generally outperformed the broader market, making these equity awards valuable retention tools for key executives. The timing in mid-February aligns with many companies' annual compensation cycles, following year-end performance reviews and board compensation committee meetings.

Investors should note that these grants will eventually increase the share count as they vest, though the dilution effect is typically minimal for a company of Zoetis's size, with a market capitalization exceeding $75 billion. The awards also create future selling pressure as insiders may liquidate vested shares for diversification or tax obligations.

The concentration of awards on a single date and the inclusion of nearly all senior leadership suggests this is Zoetis's primary annual equity grant cycle. Future SEC filings will reveal the specific vesting schedules and performance conditions attached to these awards, providing additional insight into how the company structures long-term incentives.